| WHO. Guidelines for the Screening, Care and Treatment of Persons with Chronic Hepatitis C Infection [EB/OL]. (2016-4) [2019-10-07]. https://apps.who.int/iris/handle/10665/205035. |
| FOSTER G R. Past, Present, and Future Hepatitis C Treatments [J]. Seminars in Liver Disease, 2004, (Suppl 2): 97-104. |
| RONG L B, PERELSON A S. Mathematical Analysis of Multiscale Models for Hepatitis C Virus Dynamics under Therapy with Direct-Acting Antiviral Agents [J]. Mathematical Biosciences, 2013, 245(1): 22-30. doi: 10.1016/j.mbs.2013.04.012 |
| RONG L, GUEDJ J, DAHARI H, et al. Analysis of Hepatitis C Virus Decline During Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model [J]. PLoS Comput Biol, 2013, 9(3): e1002959. doi: 10.1371/journal.pcbi.1002959 |
| GUEDJ J, DAHARI H, RONG L, et al. Modeling Shows that the NS5A Inhibitor Daclatasvir Has Two Modes of Action and Yields a Shorter Estimate of the Hepatitis C Virus Half-Life [J]. PNAS, 2013, 110(10): 3991-3996. doi: 10.1073/pnas.1203110110 |
| GUEDJ J, NEUMANN A U. Understanding Hepatitis C Viral Dynamics with Direct-Acting Antiviral Agents Due to the Interplay Between Intracellular Replication and Cellular Infection Dynamics [J]. Journal of Theoretical Biology, 2010, 267(3): 330-340. doi: 10.1016/j.jtbi.2010.08.036 |
| QUINTELA B M, CONWAY J M, HYMAN J M, et al. A New Age-Structured Multiscale Model of the Hepatitis C Virus Life-Cycle During Infection and Therapy with Direct-Acting Antiviral Agents [J]. Frontiers in Microbiology, 2018, 9: 601. doi: 10.3389/fmicb.2018.00601 |